Indoleamine 2,3-dioxygenase 1 (IDO1) was first recognized as an immune regulator in pregnancy (1), and subsequently, in numerous experimental and clinical settings, including autoimmune diseases, chronic inflammation, transplantation, and neoplasia (2). This evidence concerns the gene IDO1 and neoplasm.